Here are the 10-K annual reports from 60 Degrees Pharmaceuticals, Inc. (SXTP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SXTP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SXTP filings page.
60 Degrees Pharmaceuticals, Inc. files its annual report describing a specialty infectious disease business built around tafenoquine and celgosivir. The company markets Arakoda for malaria prevention and is developing tafenoquine for tick‑borne babesiosis, veterinary babesiosis and respiratory fungal and viral infections.
It strengthened its balance sheet through multiple 2024–2026 equity raises, including at‑the‑market programs and several registered direct and private warrant offerings that collectively brought in several million dollars of net proceeds. The report also details an extensive patent and trademark portfolio and ongoing clinical trials intended to support potential label expansions and new products.